Tesamorelin vs ipamorelin: what the evidence and the law say about each

Tesamorelin is the full 44-amino-acid sequence of growth hormone-releasing hormone, GHRH, with a hexenoyl group added to the first amino acid ^[1]. That change makes it resistant to DPP-4, the enzyme that inactivates native GHRH ^[2]. It acts on the GHRH receptor of the pituitary.

Ipamorelin is a synthetic five-amino-acid peptide that acts on a different receptor on the same pituitary cells: the ghrelin receptor, GHSR-1a ^[3]. Ghrelin is the hunger hormone, and it is also a second, independent trigger for growth hormone release. In the original animal work ipamorelin released growth hormone without raising ACTH, cortisol or prolactin, which set it apart from older peptides of its type ^[3].

Because the two act through separate receptors, a GHRH-type and a ghrelin-type peptide given together produce a larger growth hormone pulse than either alone ^[4]. That effect is the reason blends exist. It has been measured on hormone tests, not on body composition or health outcomes.

Neither lingers. The Egrifta WR label gives tesamorelin an elimination half-life of 11 minutes ^[1]. Ipamorelin's terminal half-life in the one human pharmacokinetic study was about two hours ^[5].

Tesamorelin was approved in 2010 as Egrifta for reducing excess abdominal fat in adults with HIV who have lipodystrophy ^[6]. The current product, Egrifta WR, was approved in March 2025 at 1.28 mg once daily ^[1].

Two 26-week Phase 3 trials, 806 patients in all, measured visceral fat by CT scan ^[1][7][8]. Visceral fat fell by 18% and 14% on tesamorelin, against a rise of 2% and a fall of 2% on placebo. Body weight did not change in either trial, and the label states that tesamorelin is not indicated for weight loss ^[1].

Outside HIV, a 20-week randomised trial in 152 older adults found improved executive function ^[9], and a trial in people with HIV and fatty liver disease found less liver fat ^[10]. Neither became an approved use.

Ipamorelin's human record is short. A 1999 study in healthy men, eight per dose group, given by intravenous infusion, measured its pharmacokinetics and the growth hormone pulse it produced ^[5].

The only clinical programme was for postoperative ileus, the stalled bowel after abdominal surgery. In the published Phase 2 trial, 117 patients after bowel resection received intravenous ipamorelin or placebo twice daily for up to a week. The median time to a tolerated solid meal was 25.3 hours against 32.6, a difference that was not statistically significant ^[11]. A second Phase 2 trial of 320 patients was completed in May 2014 and has no results posted on ClinicalTrials.gov ^[12]. No later trial is registered, and ipamorelin has never been approved in the US or, as far as the European, UK, Australian and Canadian regulators' databases show, anywhere else ^[13].

No trial has tested ipamorelin for muscle, fat loss, recovery or ageing.

Tesamorelin is a biologic. In February 2020 FDA defined a protein as any chain of more than 40 amino acids ^[14], and on 23 March 2020 those products moved from the drug framework to the biologics framework. Tesamorelin, at 44 amino acids, moved with them; its labels carry a biologics licence number, BLA 022505 ^[1]. FDA told compounders that month that transitioning biological products are not eligible for the compounding exemptions in sections 503A and 503B ^[15]. The lawful product is branded Egrifta.

Ipamorelin is on no list that allows it. Its nomination for the 503A bulks list was withdrawn in September 2024, after FDA had placed it in Category 2, the category for substances with significant safety concerns ^[16]. It has not been added to the 503A list, and under the separate policy for outsourcing facilities it remains in Category 2 ^[17].

So compounded versions of both are sold, and neither is compounded within the rules. Our regulatory tracker follows each peptide's status.

Tesamorelin's label lists arthralgia, injection-site redness and itching, pain in the extremities, peripheral swelling and muscle pain as the most common reactions, each above 5% ^[1]. It can raise blood glucose. It is contraindicated in active cancer, in people whose pituitary has been damaged or removed, and in pregnancy.

Ipamorelin's safety data comes from hospital patients after surgery, where adverse events were about as common on placebo as on the drug (94.8% against 87.5%) ^[11]. That tells us little about healthy adults using it for months.

Anything that raises growth hormone and IGF-1 carries the same general cautions: not with active cancer, care with impaired glucose tolerance, and IGF-1 checked by the prescriber.

The evidence gap is wide. Tesamorelin has shown a measurable effect on visceral fat in a defined population, with a known side-effect profile. Ipamorelin has a pharmacokinetic study and a failed trial in a different condition.

The legal picture is the same for both: the only lawful product between them is branded Egrifta. Anything else on offer, whether a compounded "tesamorelin" or an ipamorelin blend, sits outside FDA's compounding rules, whatever the seller says. If either is being considered, ask the prescriber which pharmacy makes it and under which provision. The other two comparisons in this group are sermorelin vs tesamorelin and sermorelin vs ipamorelin.

This page is informational and is not medical advice. It compares published evidence and regulatory status; it cannot tell you whether either peptide is appropriate for you. Both raise growth hormone and IGF-1 and are unsuitable for people with active cancer, and tesamorelin can raise blood glucose. Whether to start, what to use and how to monitor it are decisions for a licensed prescriber who knows your medical history. Last reviewed October 2026.